LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

Addressing Barriers to Prompt, Early Treatment for Diabetic Retinopathy and Diabetic Macular Edema

By: Dilsher Dhoot, MD

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1.25

Diabetic retinopathy (DR) is typically asymptomatic in its early stages. Therefore, best practice guidelines recommend people with diabetes have annual eye exams to screen for DR, nonproliferative DR, and diabetic macular edema to allow for early detection and timely treatment.

This virtual symposia hosted by Dr. Dilsher Dhoot is designed to foster collaboration in provider networks and encourage discussions on the latest trial data and clinical experience related to the importance of imaging and how early treatment can preserve vision in patients with diabetes. Other topics of discussion will include how practices have adapted as a result of the COVID-19 pandemic; the benefits of telemedicine; longer-duration therapies that require fewer visits to the clinic; and ways to improve communication with interdisciplinary care providers.

This certified CE educational activity is designed for optometrists involved in the management of patients with diabetic eye diseases.

Expiration Date: Saturday, July 1, 2023
Release Date: July 23, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the benefits of telemedicine for continued screening of diabetic patients for diabetic retinopathy (DR) and diabetic macular edema (DME) in order to provide timely treatment.
  • Execute appropriate referrals of patients with DR and DME by working with your network to understand the need for timely referrals to a retina specialist based on the latest clinical data.
  • Interpret clinical data supporting the treatment of patients with moderate NPDR without macular edema with anti-VEGF therapy.
  • Discuss longer duration therapies for DME and NPDR that are currently under investigation.

Accreditation and Designation Statement

Evolve is an approved COPE Administrator.

Sponsored by:
This activity, COPE Activity Number , is accredited by COPE for continuing education for optometrists. 
This course is approved for 1.25 hours CE. 
Course #: 73495-PB
Activity #: 122184

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Dilsher Dhoot, MD

California Retina Consultants/Retina Consultants of America
Santa Barbara, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Dilsher Dhoot, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Alimera, Bayer, Eyepoint, Genentech, Regeneron, and Novartis. Grant/Research Support: Genentech and Regeneron. Speaker’s Bureau: Alimera, Genentech, Eyepoint, Novartis, and Regeneron. Stock/Shareholder: Vortex Surgical

The Evolve staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals.

Begin Course